Vir Biotechnology, a clinical-stage biopharma focused on infectious diseases and oncology, reported 7.6% revenue decline in 2025 to $68.6 million, continuing its trend of net losses with a net loss of $438 million. The company remains heavily dependent on third-party collaborations for development and manufacturing, lacks a diversified commercial product portfolio beyond sotrovimab, and faces regulatory and operational risks. Cost-saving restructuring initiatives contributed to improved operating income margins, but significant cash burn persists. Future growth hinges on clinical progress of pipeline candidates like VIR-5500 under a new Astellas collaboration, while regulatory environments and reimbursement pressures pose ongoing challenges. Vir’s capital position is robust but constrained by high R&D expenses and no dividend or buyback programs.